Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Charles River Laboratories International, Inc. (NYSE: CRL) provides direct access to the company’s regulatory disclosures, along with AI-powered tools that help interpret complex documents. Charles River operates in research and development in biotechnology within the professional, scientific, and technical services sector, and its filings offer detailed insight into how it manages growth, risk, governance, and capital allocation.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand segment performance across Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. These reports typically discuss demand trends, restructuring initiatives, portfolio refinement, and the use of non-GAAP measures that exclude items such as acquisition-related amortization, restructuring costs, and certain legal expenses. AI summaries can highlight key sections, such as discussions of organic revenue, operating margins, and the rationale for using non-GAAP metrics.
Current reports on Form 8-K are especially important for tracking material events at Charles River. Recent 8-K filings have described planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS, updates on Discovery and Safety Assessment demand indicators, the outcome of an SEC Division of Enforcement investigation into non-human primate sourcing, strategic review outcomes, and leadership changes including CEO succession and executive compensation arrangements. AI analysis can surface these items, explain their context, and point to related risk factor or management discussion sections in periodic reports.
Users interested in governance and executive arrangements can examine 8-K and 8-K/A filings detailing appointments, resignations, and compensation terms for senior leaders, as well as board decisions on stock repurchase authorizations and change-in-control agreements. While insider trading activity is disclosed separately on Forms 3, 4, and 5, this page is designed to link related ownership and compensation information to the broader narrative in 10-Ks, 10-Qs, and 8-Ks.
All filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help readers quickly identify the main points of lengthy documents, such as how acquisitions like K.F. (Cambodia) Ltd. and PathoQuest SAS are expected to affect Discovery and Safety Assessment or Biologics Testing operations, or how restructuring and portfolio divestitures relate to the company’s focus on core scientific capabilities and long-term shareholder value.
Invesco Ltd. has disclosed a significant ownership position in Charles River Laboratories International Inc. common stock. As of 12/31/2025, Invesco may be deemed to beneficially own 2,696,150 shares, representing 5.5% of the outstanding common shares, held for its investment advisory clients.
Invesco reports sole voting power over 2,686,062 shares and sole dispositive power over 2,696,150 shares, with no shared voting or dispositive power. The holdings are stated to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Wellington Management Group LLP and related entities filed an amended Schedule 13G reporting beneficial ownership of 1,749,213 shares of Charles River Laboratories International, Inc. common stock, representing 3.55% of the class.
The Wellington filers report no sole voting or dispositive power, with shared voting power over 1,404,878 shares and shared dispositive power over 1,749,213 shares. The securities are owned of record by clients of various Wellington investment advisers, which have the right to receive dividends and sale proceeds.
The filers certify the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Charles River Laboratories. No single client is reported to hold more than five percent of the class.
Charles River Laboratories International EVP Joseph W. LaPlume reported equity transactions in company stock. On January 30, 2026, he acquired 5,456 shares of common stock at $0 when performance share units granted on May 26, 2023 vested after meeting performance goals. On the same date, 1,749 shares were withheld and disposed of at $211.68 per share, typically reflecting taxes due on the vesting. After these transactions, he directly owned 27,423 shares of common stock.
Charles River Laboratories International executive Victoria L. Creamer reported stock transactions involving company common shares. On 01/30/2026, she acquired 5,006 shares of common stock at a price of $0, following the achievement of performance goals under performance share unit awards originally granted on May 26, 2023.
On the same date, she disposed of 1,296 common shares at a price of $211.68 per share. After these transactions, she directly owned 26,072 shares of Charles River Laboratories common stock in her capacity as EVP & Chief People Officer.
Charles River Laboratories International, Inc. Chairman, President and CEO James C. Foster reported equity transactions in company common stock. On January 30, 2026, he acquired 39,031 shares at $0, reflecting performance share units that vested after meeting performance goals from awards granted on May 26, 2023.
On the same date, he disposed of 14,664 shares at $211.68 per share, leaving 253,677 directly held shares. The filing also reports indirect holdings, including 5,423 shares in a 2024 GRAT, 20,000 shares in a 2025 GRAT, additional trust-held shares, and 10,000 shares held by his spouse.
Charles River Laboratories executive Birgit Girshick reported stock transactions tied to equity awards. On January 30, 2026, she acquired 9,500 shares of common stock at $0, reflecting performance goals achieved under performance share units granted on May 26, 2023. On the same date, 3,061 shares were disposed of at $211.68 under a code "F" transaction, typically used for tax withholding, leaving 26,913 shares held directly. Separately, 45,470 shares are held indirectly in a revocable trust controlled by her, following an exempt transfer under Rule 16a-13.
Charles River Laboratories International, Inc. executive Michael Gunnar Knell, CSVP, CAO and Interim CFO, reported equity-related transactions in company common stock. On January 30, 2026, he acquired 1,668 shares at $0 per share, reflecting performance share units earned from awards granted on May 26, 2023.
On the same date, Knell disposed of 526 shares of common stock at $211.68 per share. After these transactions, he directly held 14,602 shares of Charles River Laboratories common stock.
Charles River Laboratories International executive Mark Mintz, EVP and Chief Information Officer, reported equity compensation activity in company stock. On January 30, 2026, he acquired 1,797 shares of common stock at $0, issued after meeting performance goals from performance share unit awards granted on May 26, 2023. On the same date, 655 shares of common stock were disposed of at $211.68 per share under transaction code F. Following these transactions, Mintz directly owned 7,492 shares of Charles River common stock.
Charles River Laboratories International, Inc. officer Shannon M. Parisotto reported equity award activity in company stock. On January 30, 2026, Parisotto acquired 4,236 shares of common stock at $0 per share following the achievement of performance goals under performance share unit awards originally granted on May 26, 2023.
On the same date, 1,067 shares of common stock were disposed of at $211.68 per share, typically reflecting shares withheld to cover taxes. After these transactions, Parisotto directly held 15,184 shares, and indirectly held 982 shares through a revocable trust and 28,510 shares through Karpathos Investments LLC.
Charles River Laboratories International executive reports small stock sale. Executive Vice President of Corporate Strategy & Development Joseph W. LaPlume sold 400 shares of the company's common stock on 08/22/2025 at a price of $163.72 per share. After this transaction, he directly beneficially owned 23,716 shares of Charles River Laboratories common stock.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
